Search This Board: 
Created: 05/28/2020 09:24:19 AM - Followers: 8 - Board type: Free - Posts Today: 0
Here is an extremely underpriced (trading under cash) and undiscovered biotech stock :

(TRVI-DD) Market Cap $49 million / Cash $53 Million or Cash untill Q4 2021 /Phase 3 Drug targeting Prurigo Nodularis with NO approved treatment for this indication to date a potential Blockbuster .Company has only 17.8 million outstanding shares almost all shares held by Insiders & institutional investors (see below) .This MASSIVE underpriced extreme low float stock could hit $20+ on positive Phase 3 readout and more with FDA approval .GL

Trevi Therapeutics (TRVI)

Market Cap: $49 Million
Cash: $53 Míllion (or untill Q4 2021)
Price: $2.79

Shares Out: 17.8 Million

Company Presentation

Major Shsareholders:

TPG Capital, L.P...6.3M
New Enterprise ...5.9M
Omega Fund ...1.3M
Lundbeckfond ...1.2M
Fidelity ...792.7K
Franklin ...587.3K
Richard King ...347.2K
Meeker (David P)...311.8K
Good (Jennifer L)...206.2K
Sciascia (Thomas R)...193.7K

BMO Capital Markets analyst Gary Nachman initiated coverage of shares of Trevi with an Outperform rating and $15 price target.

The Thesis

Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note.

Nalbuphine ER is an oral formulation of Nalbuphine, an injectable in use for decades to treat pain, and it is the only opioid-based pain drug not scheduled by the DEA, the analyst added.

The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted.

The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.

A larger Phase 2b/3 study for the lead indication for which enrollment has begun, according to the analyst, has a good chance of success. Data from the study is expected in the first half of 2020, he added.

"We see a compelling valuation at current levels after recent IPO, with further optionality for Nalbuphine ER in additional indications beyond PN," BMO concluded.

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
I want 2.75s starkd748 08/19/2022 04:24:27 PM
Come on keep moving starkd748 08/03/2022 10:17:08 AM
Held after gap fill...Glad I loaded Fri starkd748 07/05/2022 02:28:15 PM
#22 Yup no reversal after gap fill then it' starkd748 06/29/2022 12:27:17 PM
Gap fill time making lower lows...I'll wait starkd748 06/29/2022 11:25:58 AM
Trevi Therapeutics Reports Positive Results from the Ph2b/3 subslover 06/29/2022 08:05:40 AM
Thanks 7zienza7 04/08/2022 06:16:52 AM
private placement pops are different then offerings, offerings TrendTrade2016 04/08/2022 05:57:29 AM
I'm a bit confused...the news was about dilution, 7zienza7 04/07/2022 04:31:33 PM
EOD near HOD ... news today .... wile.e.coyote 04/07/2022 04:06:09 PM
TRVI ready to rock!!!!!! TrendTrade2016 04/07/2022 12:02:51 PM
TRVI low floater taking off!! TrendTrade2016 04/07/2022 10:40:51 AM
Seriously overbought, all out at $1.73 $oldier Hard 03/09/2022 09:57:21 AM
$TRVI, this works! $oldier Hard 03/01/2022 12:53:32 PM
$TRVI 5 times it's avg 10 day volume, $oldier Hard 11/11/2021 01:46:40 PM
You still here with me? $oldier Hard 10/25/2021 04:05:06 PM
I agree. $oldier Hard 10/13/2021 08:27:24 PM
Very interesting here. ttottip 10/13/2021 12:31:48 PM
#7 Brand new Reddit forum discussion TRVI. frugalNorwegian 09/04/2021 05:33:52 PM
#6 TRVI Updated information from the most recent corporate presentation. Long_Holder 10/06/2020 05:09:51 PM
#5 UPPPP 13%+ BioSpecialist 06/03/2020 07:16:35 AM
#4 RALLYYYYYYYYYYYYYYYYYYYYYYyyy BioSpecialist 06/01/2020 03:43:14 PM
#3 Up 7%+ on no volume so once we BioSpecialist 05/29/2020 07:58:04 AM
#2 Major breakout to $5+ could start anytime now BioSpecialist 05/28/2020 12:39:51 PM
#1 One of the cheapest biotech you can get BioSpecialist 05/28/2020 09:33:36 AM
Post Subject